Your browser doesn't support javascript.
loading
Exploration de l'hémolyse associée à la drépanocytose et perspectives thérapeutiques spécifiques: Sickle cell disease hemolysis investigations and targeted therapeutics prospects.
Bartolucci, P.
Affiliation
  • Bartolucci P; Recherche IH, EFS Créteil-Mondor, Créteil, France; IMRB Inserm 955, équipe Pirenne, Créteil, France; Centre de références des syndromes drépanocytaires majeures, hôpital Henri-Mondor, Créteil, France; Université Paris-Est Créteil, Créteil, France. Electronic address: pablo.bartolucci@aphp.fr.
Rev Med Interne ; 44(4S1): 4S7-4S11, 2023 Nov.
Article in Fr | MEDLINE | ID: mdl-38049244
ABSTRACT
Sickle Cell Anemia is a disease with a strong vascular tropism. Beyond anemia, the pathophysiological mechanisms responsible for hemolysis, directly affect both acute and chronic vascular damages, thus resulting in a systemic disease. Understanding the different types of hemolysis underline the need for novel specific biomarkers. Targeted therapeutic approaches for these pathophysiological pathways are necessary to improve Sickle Cell patients' prognosis. Finally, given its complexity, Sickle Cell Disease is often used as a "proof of concept" for other pathologies. It seems likely that the rapidly evolving knowledge in this field will also benefit other diseases. © 2023 Société nationale française de médecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemolysis / Anemia, Sickle Cell Limits: Humans Language: Fr Journal: Rev Med Interne Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemolysis / Anemia, Sickle Cell Limits: Humans Language: Fr Journal: Rev Med Interne Year: 2023 Document type: Article